Selected Publications
Swanson HD, Hakim H, Hijano DR, Morton T, Cross S, Inaba H, Jeha S, Pui CH, Karol SE. Vaccines against SARS-CoV-2 are safe to administer in patients with antibodies to pegaspargase. Cancer Med 2022 Jul 15. doi: 10.1002/cam4.5011.
Lambrix AA, Swanson HD, Pauley JL, Bragg AW, Carias DC, Bourque MS, Zhou Y, Cheng C, Greene WL, Maron G. Experience using intravenous posaconazole in pediatric and young adult oncology patients. J Antimicrob Chemother. 2020; 75 (12): 3682-3687.
Panetta JC, Liu Y, Swanson HD, Karol SE, Pui CH, Inaba H, Jeha S, Relling MV. Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase. Pediatr Blood Cancer. 2020 Jul;67(7):e28244. doi: 10.1002/pbc.28244. Epub 2020 Apr 23.
Swanson HD, Panetta JC, Barker PJ, Liu Y, Inaba H, Relling MV, Pui CH, Karol SE. Predicting success of desensitization after pegaspargase allergy. Blood. 2020 Jan 2;135(1):71-75.
Liu Y, Smith CA, Panetta JC, Yang W, Thompson LE, Counts JP, Molinelli AR, Pei D, Kornegay NM, Crews KR, Swanson H, Cheng C, Karol SE, Evans WE, Inaba H, Pui CH, Jeha S, Relling MV. Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. J Clin Oncol. 2019 Aug 10;37(23):2051-2061.
Quinn M, Fannin JT, Sciasci J, Bragg A, Campbell PK, Carias D, Crews KR, Gregornik D, Jeha S, Maron G, Pauley JL, Swanson, HD. Wolf J, Greene W. Pentamidine for prophylaxis against Pneumocystis jirovecii pneumonia in pediatric oncology patients receiving immunosuppressive chemotherapy. Antimicrob Agents Chemother. 2018; 62: e00173-18.
Scott JR, Zhou Y, Cheng C, Ward DA, Swanson HD, et al. Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients. Pediatric Blood and Cancer. 2015; 62:1518-1522.
Last update: October 2022